^
Association details:
| Biomarker: | ER positive |
|---|---|
| Cancer: | Estrogen Receptor Positive Breast Cancer |
| Drug: | fulvestrant (Selective estrogen receptor degrader) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
08/01/2018
Excerpt:
Fulvestrant is indicated for the treatment of estrogen receptor positive, locally advanced or metastatic breast cancer in postmenopausal women…
Source:
Title:
Imaging of the effects of fulvestrant on the availability of estrogen receptor binding sites in patients with metastatic breast cancer
Excerpt:
...Patients with a history of histological proven ER-positive primary breast cancer and, whenever available, histological proven ER-positive recurrence. ...
Trial ID:
Source:
Title:
A Randomized, Open-label, Multicenter, Phase II Study Comparing the Effects on Proliferation and the Efficacy and Tolerability of Fulvestrant (FASLODEX™) 500 mg with Fulvestrant (FASLODEX™) 250 mg when given as Neoadjuvant Treatment in Postmenopausal Women with Estrogen Receptor Positive Breast Cancer (T2, 3, 4b, N0-3, M0)
Excerpt:
...Histologically/cytologically confirmed invasive breast cancer, ER positive as defined by the local laboratory3. ...
Trial ID:
Less C2 evidence
Source:
Title:
Efficacy of fulvestrant in treating postmenopausal patients with estrogen receptor-positive metastatic breast cancer and prognostic analysis
Excerpt:
Fulvestrant has definite efficacy in treating ER-positive metastatic breast cancer and results in tolerable adverse reactions, while it notably extends the mPFS of patients who have no visceral metastasis and receive no prior tamoxifen or endocrine therapy, but the first-line fulvestrant therapy in this study.
Source:
Title:
Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER+) breast cancer: A case report and narrative review
Published date:
07/24/2020
Excerpt:
Here, we present a case report and make a narrative review of concomitant fulvestrant with radiation therapy for unresectable locoregional recurrent ER+ breast cancer. There was a good clinical response, enabling curative chance with radiation therapy to a total dose of 60 Gy. Computed tomography scan revealed no evidence of residual tumor.
DOI:
10.1097/MD.0000000000021344
Source:
Title:
Enhanced ER+ tumor growth inhibition of fulvestrant from effective oral delivery yielding elevated plasma concentrations
Published date:
12/02/2023
Excerpt:
In a cell-derived xenograft (CDX) study utilizing ER+ MCF-7 tumors implanted in a thymic nude mice, once daily dosing via oral gavage of oral fulvestrant at 125 mg/kg was able to achieve a statistically significant 55% reduction in tumor growth by day 42 relative to a 50 mg/kg dose of the IM formulation delivered subcutaneously once per week...
Source:
Title:
OR22-2 -Thyroid Hormone and Estrogen Promote Endocrine Resistance, Proliferation, Dedifferentiation, and Cancer Stem Cells in Steroid Receptor-Positive Breast Cancers
Published date:
01/21/2021
Excerpt:
ER+ PDX tumors were implanted into NSG mice containing E2 pellet and subsequently treated with TH, Tamoxifen (Tam), Fulvestrant (ICI) or Met….Both ICI and Met provided significant attenuation of tumor growth in vivo….Our data suggest that the use of Tam did not dampen tumor growth whereas a full ER-antagonist (ICI) or Met attenuated E2-TH mediated cross-talk and tumor growth.
DOI:
10.1158/1078-0432.CCR-20-264
